ALK and non-small cell lung carcinoma: Third-generation anaplastic lymphoma kinase (ALK)-TKIs, including brigatinib, ensartinib and lorlatinib, each achieved an intracranial objective response rate of 70% in clinical trials (NCT02737501, NCT03215693 and NCT03215693) involving patients with ALK fusion gene-positive NSCLC [39–41].